Literature DB >> 1891217

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients.

P Y Lee1, H Shao, C B Camras, S M Podos.   

Abstract

The effect on intraocular pressure (IOP) of adding prostaglandin F2 alpha-1-isopropyl ester (PGF2 alpha-IE) to timolol was studied in 21 eyes of 13 patients with newly diagnosed primary open-angle glaucoma that was inadequately controlled with timolol alone. After at least 2 weeks of twice daily timolol 0.5% therapy, PGF2 alpha-IE, 0.5 microgram in 30 microliters, was topically applied twice daily at 8 AM and 8 PM, 5 minutes before each timolol dose, for 7 days. Intraocular pressures were measured before timolol treatment, and at 8 AM, 8:30 AM, 12 PM, 2 PM, and 4 PM on the day before the addition of PGF2 alpha-IE, and on day 1 and on day 7 of combined therapy. Mean IOP was 39 +/- 2 mmHg (+/- standard error) before timolol therapy and 31 +/- 2 mmHg after at least 2 weeks of treatment with timolol alone. A significant (P = 0.004) further reduction of IOP was first observed 4 hours after the first dose of PGF2 alpha-IE, which was maintained throughout the duration of combined therapy. During the last day of combined treatment and at 12 hours after the final dose, IOP was reduced a mean of 6 to 9 mmHg (mean, 9.0 +/- 1.5 mmHg at 12 hours) below baseline values obtained with timolol alone. These results indicate that adding PGF2 alpha-IE in patients treated with timolol causes a further reduction of IOP that may prove to be clinically useful in glaucoma therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891217     DOI: 10.1016/s0161-6420(91)32173-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

Authors:  M Kimal Arici; A Topalkara; C Güler
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.

Authors:  J P Nordmann; M Söderström; J F Rouland; F Malecaze
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 3.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Latanoprost--a promising new glaucoma drug.

Authors:  S Nagasubramanian
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

Review 5.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 6.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

7.  Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.

Authors:  Oliver Schwenn; Barbara Heckmann; Claudia Guzy; Paul J Miller
Journal:  BMC Ophthalmol       Date:  2010-09-08       Impact factor: 2.209

8.  A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.

Authors:  M Diestelhorst; L-I Larsson
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

9.  Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure.

Authors:  A H Rulo; E L Greve; P F Hoyng
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

10.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.

Authors:  A Alm; I Widengård; D Kjellgren; M Söderström; B Friström; A Heijl; J Stjerschantz
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.